BUSINESS NEWS
Geron Announces Publication of Studies Demonstrating Hematopoietic Stem Cells Differentiated From Human Embryonic Stem Cells Engraft and Establish Hematopoiesis in Animals
Geron Corporation announced today the publication of studies demonstrating that hematopoietic stem cells (HSCs) derived from human embryonic stem cells (hESCs) can establish hematopoiesis in mouse models, leading to production of all major human blood cell types.
Article
Geron Announces Publication Describing Animal Cell-Free Derivation of Human Embryonic Stem Cells
Geron Corporation announced today the publication of studies which show that human embryonic stem cells (hESCs) can be derived without the use of animal cell feeders.
Article
Geron Announces Publication of Studies Showing Oligodendrocyte Progenitors Derived From Human Embryonic Stem Cells Induce Functional Recovery After Spinal Cord Injury
Geron Corporation (Nasdaq: GERN) announced today the publication of studies showing that oligodendrocyte progenitors, differentiated from human embryonic stem cells (hESCs), produce functional improvements in rats with spinal cord injuries.
Article
Cellerant Therapeutics Raises $16 Million to Advance Stem Cell-Based Therapies for Life-Threatening Diseases
Cellerant Therapeutics Inc. announced that it has raised $16 million in a series B financing led by Novel Bioventures.
Article
CryoLife Announces Implant of its Cryopreserved Orthopaedic Tissues Treated With the Clearant Process
CryoLife, Inc., a biomaterials and biosurgical device company, announced today the first human implant of its cryopreserved orthopaedic tissues utilizing the Clearant Process(R).
Article
CryoLife Selects Clearant, Inc. to Sterilize Implant of its Cryopreserved Orthopaedic Tissues; Leading Tissue Bank Adopts The CLEARANT PROCESS-R- For The First Time
Clearant, Inc., the developer of the CLEARANT PROCESS(R) for pathogen inactivation announced today that CryoLife, Inc., a biomaterials and biosurgical device company, had completed their first human implant of its cryopreserved orthopaedic tissues utilizing the CLEARANT PROCESS(R).
Article
Dow and Cytogen Agree to Develop PSMA Antibody
Cytogen Corporation, a product-driven biopharmaceutical company, and Dowpharma contract manufacturing services, a business unit of The Dow Chemical Company, announced a collaboration to create a targeted oncology product designed to treat prostate and other cancers.
Article
European Patent For Trovax® Covering 5T4 Tumour Antigen-Targeted Immunotherapy, Oxford Biomedica
Oxford BioMedica, the leading gene therapy company, today announced that the European Patent Office has granted a key patent that provides broad protection for Oxford BioMedica’s lead product, TroVax.
Article
Favrille, Inc. Announces Phase 2 Clinical Trial Results For FavId(R) Following Autologous Stem Cell Transplantation To Be Presented During American Society of Clinical Oncology
Article
ImmunoGen, Inc. Announces Appointment of Daniel M. Junius as Chief Financial Officer
Article
Ono Pharmaceutical Company, Ltd. And Medarex, Inc. (MEDX) Enter Into Collaborative Research Agreement On Antibody Product
Ono Pharmaceutical Co., Ltd. and Medarex, Inc. announced today that they have entered into a collaborative research agreement to research and develop a fully human anti-PD-1 antibody for the potential treatment of cancer.
Article
PhereSys Therapeutics Extends Its National Therapeutic Apheresis Services Roll-out to San Diego and Appoints Jerry Kolins, MD As Western Regional Medical Director
Pheresys Therapeutics Corporation (“PhereSys”) announced today that it has expanded its therapeutic apheresis (“TA”) services to the greater San Diego area, and continues to build its top-tier management team with the appointment of Jerry Kolins, MD, FACHE as its Western Regional Medical Director.
Article
Viragen Licenses ‘Anti-CD55 Antibody’ Cancer Therapy from Cancer Research Technology
Viragen, Inc. (AMEX: “VRA”) and Cancer Research Technology Limited (U.K.) today announced a license agreement that provides Viragen with worldwide exclusive rights to commercialize the anti-CD55 antibody, which is currently in preclinical development for the treatment of a broad range of cancers.
Article
MARKET REPORTS
Malachite Management has joined forces with established and reputable authors and publishers to bring you the following market reports outlining the very latest in Cell Therapy, Gene Therapy, and Immunotherapeutic approaches to Cancer.
“Cell Therapy – Technologies, Markets, and Companies” is over 400 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the cell therapy industry worldwide.
For more information, including order forms, please see:
Cell Therapy Report Summary
Cell Therapy Sample Chapter
Cell Therapy Table of Contents Vol. 1 Vol. 2
Cell Therapy Order Form
“Gene Therapy – Technologies, Markets, and Companies” is over 500 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the gene therapy industry worldwide.
For more information, including order forms, please see:
Gene Therapy Report Summary
Gene Therapy Table of Contents Vol. 1 Vol. 2
Gene Therapy Order Form
The Immunotherapy Reports cover the most recent developments in the immunotherapeutic approaches to cancer.
A Shift in Cancer Immunotherapy Strategies?
Immunotherapy Strategies Executive Summary
Immunotherapy Strategies Table of Contents
Future Perspectives in Cancer Immunotherapy
Future Perspectives Executive Summary
Future Perspectives Table of Contents
Immunotherapy Reports Order Form